Androgen receptor--an update of mechanisms of action in prostate cancer
- PMID: 11011957
- DOI: 10.1007/s002400000111
Androgen receptor--an update of mechanisms of action in prostate cancer
Abstract
Androgen receptor (AR), a key nuclear transcription factor in the prostate gland, is expressed in all histological types and stages of prostate cancer. The AR regulates proliferation of prostate cancer cells by stimulation of cyclin-dependent kinases. However, in some prostate tumors AR stimulates expression of cell cycle inhibitors, thus leading to down-regulation of cellular proliferation. Androgens, by activation of the AR, control differentiation of prostate cells and synthesis of neutral lipids. There are several mechanisms by which prostate cancer cells adapt to an environment with low androgen supply during endocrine therapy. The AR expression and activity increase in several cell lines that are used as an in vitro model for monitoring changes during long-term androgen ablation. Mutant ARs are of importance for monitoring the natural course of the disease and for determining the response to anti-androgens in metastatic lesions from prostatic carcinoma. In addition, AR activity is up-regulated by various stimulators of intracellular protein kinases. Current research efforts are focused on elucidation of function of AR coregulatory proteins, coactivators and corepressors. Their inappropriate expression and/or function might critically influence cellular events in advanced carcinoma of the prostate. It is hoped that information on these coregulatory proteins will serve as a basis for a more efficient pharmacological inhibition of the AR in advanced carcinoma of the prostate.
Similar articles
-
Androgen receptors in prostate cancer.J Urol. 2003 Oct;170(4 Pt 1):1363-9. doi: 10.1097/01.ju.0000075099.20662.7f. J Urol. 2003. PMID: 14501770 Review.
-
Expression and function of androgen receptor coactivators in prostate cancer.J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19. J Steroid Biochem Mol Biol. 2004. PMID: 15663989 Review.
-
Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.Am J Pharmacogenomics. 2001;1(4):241-9. doi: 10.2165/00129785-200101040-00001. Am J Pharmacogenomics. 2001. PMID: 12083956 Review.
-
Androgen receptor signaling in prostate cancer.Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27. doi: 10.1007/s10555-013-9474-0. Cancer Metastasis Rev. 2014. PMID: 24384911 Review.
-
Androgen-receptor gene structure and function in prostate cancer.World J Urol. 1996;14(5):329-37. doi: 10.1007/BF00184606. World J Urol. 1996. PMID: 8912473 Review.
Cited by
-
A new trick of an old molecule: androgen receptor splice variants taking the stage?!Int J Biol Sci. 2011;7(6):815-22. doi: 10.7150/ijbs.7.815. Epub 2011 Jul 6. Int J Biol Sci. 2011. PMID: 21750650 Free PMC article. Review.
-
Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.J Exp Clin Cancer Res. 2017 Aug 23;36(1):112. doi: 10.1186/s13046-017-0583-4. J Exp Clin Cancer Res. 2017. PMID: 28830537 Free PMC article.
-
Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer.PLoS One. 2013;8(2):e56592. doi: 10.1371/journal.pone.0056592. Epub 2013 Feb 22. PLoS One. 2013. PMID: 23451058 Free PMC article.
-
The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue.Cell Biosci. 2023 Mar 20;13(1):60. doi: 10.1186/s13578-023-01008-4. Cell Biosci. 2023. PMID: 36941697 Free PMC article. Review.
-
Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.Int J Cancer. 2007 Sep 1;121(5):999-1008. doi: 10.1002/ijc.22802. Int J Cancer. 2007. PMID: 17487836 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
